June 24, 2026

ERC Advanced Grants for Researchers at Universität Heidelberg

ERC Advanced Grants for Researchers at Universität Heidelberg

Funding from the European Research Council for projects at Ruperto Carola and the Central Institute of Mental Health

Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the European Research Council (ERC), an ERC Advanced Grant, which will support a project in the field of computational quantum chemistry. In the context of this project, Prof. Hamprecht is developing new approaches to machine learning able to predict the properties of molecules and materials. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola. With the ERC funding he wants to be the first to shed light on the neurobiological mechanisms connecting heat and aggression. The ERC is allocating both Prof. Hamprecht and Prof. Meyer-Lindenberg approximately 2.5 million euros each for five years to carry out their research.

With his ERC-funded project “Learning Orbital-Free Density Functional Theory” (LearningOFDFT), Prof. Hamprecht aims to develop a precise and stable calculation of molecular energies based on electron densities in what is called an orbital-free approach. To do so, the scientist and his team are working on new methods of machine learning-enhanced calculation with which the energy of molecules can be derived from the distribution of electrons in space alone. The goal of the new method is to enable precise predictions even for complex systems − distinctly faster than conventional quantum chemistry methods – and thereby contribute to resolving a problem that has been open for decades. The planned work falls under the category of basic research in quantum chemistry. In the long term, however, the results are intended to advance applied research – from the analysis of biomolecular reactions to the development of environmentally friendly materials. Fred Hamprecht has been teaching and conducting research at Heidelberg University since 2001 and heads the research group “Scientific Artificial Intelligence” at the Interdisciplinary Center for Scientific Computing.

Why high temperatures favor aggressive behavior and what processes in the brain are responsible for this is the research topic of Prof. Meyer-Lindenberg. His ERC-funded project “Neuroecological Mechanisms Linking Heat and Aggression Risk” (HOTHEAD) centers on the neuronal circuits controlling aggression and temperature regulation in the brain. They are as old as evolution and resemble one another in many species, including mice, rats, dogs and even fish. Since a rise in aggression is observed with human beings and also with these animals, Prof. Meyer-Lindenberg and his team assume there is a common biological mechanism which they wish to directly prove for the first time. The results of the ERC project are to contribute to the development of strategies with which societies can better protect themselves against the consequences of global warming. Andreas Meyer-Lindenberg has, since 2007, directed the Central Institute of Mental Health, at which he heads the Department and Clinic of Psychiatry and Psychotherapy. He holds the Professorship for Psychiatry and Psychotherapy at the Medical Faculty Mannheim of Heidelberg University.

left: Fred A. Hamprecht | © Klaus Landry
right: Andreas Meyer-Lindenberg | © Daniel Lukac / ZI

The ERC Advanced Grant of the European Research Council goes to outstanding established researchers who wish to implement a groundbreaking, ambitious research project as part of their scholarly activity. The maximum length of funding is five years.

Further information

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp